CAP can possibly enhance tumor antigen secretion and enhance CD8+ TIL cytotoxicity, potentially repolarize TAMs from the M2 to the M1 state, modulate p53‐driven CAF hierarchy towards enhanced drug sensitivity, block MSCs differentiation to CAFs that is associated with reduced cancer stemness, and function as the cargo of MSCs or their derived exosomes for enhanced delivery to the tumor loci. Here, CD8A is linked to cancer.